Updated results from a phase I/II trial of gilteritinib in combination with azacitidine/venetoclax show high CR rates and MRD negativity in frontline and relapsed/refractory FLT3-mutated AML.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address Clinical Care Options, LLC 12001 Sunrise Valley Drive Suite 300 Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
Continue